Physiomics plc (AIM: PYC), a mathematical modelling, data science and biostatistics company, announced on Monday that it has been awarded a follow-on contract with an existing UK client to support a Phase 2 clinical trial for a small molecule therapeutic targeting rheumatoid arthritis.

The project builds on previous work completed under a contract announced on 9 May 2025, where Physiomics developed a population pharmacokinetic (PK) model to inform trial design.

Project commencement is expected in 2027, reflecting client timelines for patient recruitment and data generation, with an anticipated six-month duration. Contract value is estimated between GBP116,000 and GBP169,000, with scope flexibility.

Physiomics combines expertise in modelling and simulation, biostatistics, data science and bioinformatics to support drug development and personalised medicine. Its proprietary Virtual Tumour technology and computational modelling have informed over 100 commercial projects across more than 125 targets, serving clients including Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and CRUK.